The Rx Affordability Crisis

Drug Pricing Reform and Implications for Employers & Health Plans

Wednesday, February 2

11am PT / 2pm ET

Tricia Neuman

SVP of Medicare Policy, Kaiser Family Foundation

Mark Miller

EVP of Healthcare, Arnold Ventures; Former ED of MedPAC

Cybele Bjorklund

SVP of Policy, Virta Health

For years, US policymakers from both parties have worked to improve affordability of prescription drugs with little success. Insulin in particular has been a key area of focus, as insulin prices have skyrocketed over the last decade. President Biden’s Build Back Better (BBB) legislation would make significant changes across a number of key areas, but its outlook is far from clear. 

Both the public and private sector have made numerous attempts to curb rising prescription drug costs with efforts ranging from policy proposals to permit Medicare to negotiate lower prices, and Express Script’s price caps for insulin co-payments.

Join us for a panel of top policy experts to decode the latest chatter and trends on drug pricing as we investigate the potential impact on health plan and employer benefits and spending.

We’ll cover: 

  • State of the union on drug pricing initiatives, both BBB and potential for administrative action
  • Strategic implications for employers and health plans 
  • What’s next—additional policy gaps and opportunities for diabetes reversal

Register for the webinar

Copyright © 2020 All Rights Reserved